Skip to main navigation Skip to search Skip to main content

Guidelines for mono, double and triple antithrombotic therapy

Research output: Contribution to journalReview articlepeer-review

Abstract

Guidelines for antithrombotic therapy are complex, especially if a patient has several indications that require antithrombotic therapy. In general, no patient should receive lifelong double or triple antithrombotic therapy. In this overview, we outline the most common indications for mono, double and triple antithrombotic therapy; the preferred antithrombotic therapy and the recommended duration of therapy. Both antiplatelet therapy and therapeutic anticoagulation therapy with vitamin K antagonists or direct oral anticoagulants were included. European guidelines were used or, if no European guidelines were available, the Dutch guidelines were used.

Original languageEnglish
Pages (from-to)730-737
Number of pages8
JournalPostgraduate medical journal
Volume97
Issue number1153
DOIs
Publication statusPublished - Nov 2021
Externally publishedYes

Keywords

  • Anticoagulants/administration & dosage
  • Atrial Fibrillation/complications
  • Coronary Artery Disease/complications
  • Fibrinolytic Agents/administration & dosage
  • Humans
  • Practice Guidelines as Topic
  • Thromboembolism/prevention & control
  • Vitamin K/antagonists & inhibitors

Fingerprint

Dive into the research topics of 'Guidelines for mono, double and triple antithrombotic therapy'. Together they form a unique fingerprint.

Cite this